Combination of Pneumococcal Surface Protein A (PspA) with Whole Cell Pertussis Vaccine Increases Protection Against Pneumococcal Challenge in Mice

@inproceedings{Oliveira2010CombinationOP,
  title={Combination of Pneumococcal Surface Protein A (PspA) with Whole Cell Pertussis Vaccine Increases Protection Against Pneumococcal Challenge in Mice},
  author={Maria Leonor S Oliveira and Eliane N Miyaji and Daniela M Ferreira and A. Tamariz-Martel Moreno and Patr{\'i}cia Cristina Duarte Ferreira and Fernanda Alvarenga Lima and Fernanda Lucio dos Santos and Maria Aparecida Sakauchi and C{\'e}lia S. Takata and Hisako Gondo Higashi and Isa{\'i}as Raw and Fl{\'a}via Saldanha Kubrusly and Paulo Lee Ho},
  booktitle={PloS one},
  year={2010}
}
Streptococcus pneumoniae is the leading cause of respiratory acute infections around the world. In Latin America, approximately 20,000 children under 5 years of age die of pneumococcal diseases annually. Pneumococcal surface protein A (PspA) is among the best-characterized pneumococcal antigens that confer protection in animal models of pneumococcal infections and, as such, is a good alternative for the currently available conjugated vaccines. Efficient immune responses directed to PspA in… CONTINUE READING